Nanotechnology Science and Applications, published by DOVE MEDICAL PRESS LTD, is a premier open-access journal dedicated to advancing knowledge in the fields of nanoscience and nanotechnology, particularly focusing on their applications in bioengineering, biomedical engineering, and pharmaceutical sciences. Since its inception in 2008, this journal has provided a platform for the dissemination of high-quality research that is rigorously peer-reviewed, ensuring that only the most impactful findings reach a global audience. With an impressive impact factor reflected in its recent categorization in the Q1 tier for Pharmaceutical Science and Q2 for Bioengineering and Nanoscience, it stands as a critical resource for researchers, practitioners, and students eager to explore the cutting-edge innovations within these rapidly evolving disciplines. The journal's commitment to accessibility and its robust indexing in Scopus—ranked highly in its respective categories—reinforces its importance as a leading forum for the exchange of scientific knowledge and the fostering of collaborative research in nanotechnology applications.

Journal of Pharmacy and Pharmacology, published by Oxford University Press, is a prestigious academic journal dedicated to the advancement of knowledge in the fields of pharmaceutical sciences and pharmacology. With a strong heritage dating back to 1949, this journal maintains a robust influence, as evidenced by its ranking in the second quartile (Q2) across both Pharmaceutical Science and Pharmacology categories for 2023. The journal is accessible without an open access option, ensuring traditional academic engagement and providing valuable insights for researchers and professionals. It boasts an impressive Scopus ranking, with a percentile positioning of 72nd in Pharmaceutical Science and 67th in Pharmacology. Aimed at fostering innovative research and facilitating the exchange of cutting-edge scientific knowledge, the Journal of Pharmacy and Pharmacology serves as an essential resource for scientists, students, and healthcare professionals committed to enhancing therapeutic outcomes and advancing pharmaceutical innovations.

JOURNAL OF CONTROLLED RELEASE is a premier academic journal published by Elsevier that is dedicated to advancing the field of pharmaceutical science with a focus on drug delivery systems. Established in 1984, the journal has consistently served as a vital platform for disseminating high-quality research and innovative ideas in the area of controlled release technologies. With an impressive impact factor and ranking in the Q1 category of Pharmaceutical Science, it ranks #3 out of 183 in Scopus for its field, reflecting its influence and significance within the academic community, as noted by its percentile of 98th. The journal encompasses a wide range of topics, including polymer science, pharmacokinetics, and bioengineering, ensuring it remains at the forefront of pharmaceutical advancements. While currently not offering open access options, the journal serves a diverse audience of researchers, professionals, and students who are eager to push the boundaries of knowledge in drug delivery and therapeutics. For those looking to make impactful contributions in this dynamic field, JOURNAL OF CONTROLLED RELEASE is an essential resource for both foundational studies and cutting-edge research findings.

Biomaterials Advances is a premier journal published by Elsevier, dedicated to the rapidly evolving field of biomaterials. Established in the United Kingdom, this open-access journal aims to disseminate high-quality, peer-reviewed research that explores innovative biomaterial designs and their applications in bioengineering and biomedical engineering. With an impressive 2023 impact factor reflected in its Q1 rankings across multiple categories—including Bioengineering, Biomaterials, and Biomedical Engineering—Biomaterials Advances stands out as a critical platform for scholars and practitioners faced with advancing technologies and methodologies in the realm of materials science. Covering a broad range of topics, from biocompatibility to tissue engineering, this journal provides an inclusive forum for researchers seeking to contribute to the field. Its Scopus rankings further affirm its position as a leading resource, with notable standings in Biomedical Engineering (Rank #13), Biomaterials (Rank #8), and Bioengineering (Rank #11), all within the top percentiles. Researchers and students alike are encouraged to contribute and engage with the latest findings and innovations in biomaterials through this valuable publication.

MACROMOLECULAR BIOSCIENCE, published by WILEY-V C H VERLAG GMBH, is a leading journal in the fields of bioengineering, biomaterials, biotechnology, materials chemistry, and polymers and plastics. With a convergence of scientific inquiry since its inception in 2001, the journal has established itself as a vital resource for researchers and professionals exploring the interface of molecular sciences and biosystems. It boasts impressive Scopus rankings, including Q1 status in multiple categories, reflecting its significant contribution to advancing knowledge and innovation in the polymer and biomaterials domains. While the journal does not currently offer open access options, its rigorous peer-review process ensures the publication of high-quality research that fuels academic discourse. Positioned in Weinheim, Germany, MACROMOLECULAR BIOSCIENCE aims to bridge theoretical understanding with practical applications, making it an essential reference for students, academics, and industry practitioners dedicated to the evolving landscape of macromolecular bioscience.

The Journal of Pharmaceutical Innovation, published by SPRINGER, serves as a vital resource in the fields of Pharmaceutical Science and Drug Discovery. With an ISSN of 1872-5120 and an E-ISSN of 1939-8042, this journal has been disseminating significant research findings since its inception in 2006. It is recognized for its rigorous peer-review process, maintaining a respectable ranking of Q2 in Pharmaceutical Science and Q3 in Drug Discovery as of 2023. Researchers and practitioners benefit from the journal's diverse scope, which encompasses innovative methodologies and advancements in pharmaceuticals, thereby fostering knowledge and collaboration within the scientific community. Although it does not offer Open Access options, the journal is accessible through institutional subscriptions and libraries, ensuring that critical insights in drug development and pharmacology reach a broad audience. The geographical presence of the journal in the United States underscores its influence in shaping the pharmaceutical landscape on a global scale.

The Future Journal of Pharmaceutical Sciences, published by Springer, stands as a vital resource in the realm of pharmaceutical research and innovation. Recognized for its open access initiative since 2015, this journal promotes extensive dissemination of cutting-edge discoveries, fostering collaboration among researchers, industry professionals, and students alike. With an ISSN of 2314-7245 and an E-ISSN of 2314-7253, it aims to bridge the gap between laboratory research and practical applications in the pharmaceutical sciences. Although specific metrics like HIndex and Scopus ranks are currently unavailable, the journal's commitment to high-quality, peer-reviewed content positions it as a promising platform for advancing pharmaceutical science. By engaging with this journal, contributors and readers can participate in the vibrant discourse shaping the future of drug development, therapeutic strategies, and healthcare solutions.

Pharmaceutics is a prestigious journal published by MDPI, specializing in the field of pharmaceutical sciences. With its Open Access model established in 2010, it promotes the dissemination of cutting-edge research, catering to a global audience of researchers, professionals, and students alike. Based in Switzerland, the journal has rapidly gained recognition, currently holding an impressive Q1 ranking in the pharmaceutical science category for 2023 and achieving a Scopus ranking of #32 out of 183 in the domain of Pharmacology, Toxicology, and Pharmaceutics, placing it in the 82nd percentile. The journal's objectives include advancing knowledge in drug formulation, delivery systems, and therapeutic applications, ensuring that published works contribute significantly to both academic discourse and practical applications in the pharmaceutical industry. As part of its commitment to excellence, Pharmaceutics welcomes high-quality manuscripts that inspire innovation and foster collaboration in this vital field.

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY is a premier journal published by Taylor & Francis Ltd that focuses on the latest advancements and innovations in the field of pharmaceutical science. Established in 1996, this journal has evolved to encompass a wide array of interdisciplinary studies relevant to drug development, formulation technology, and delivery systems, serving as a platform for researchers and professionals to share groundbreaking findings. With an impressive impact factor and ranked in both Q2 in Pharmaceutical Science and Q3 in Medicine (miscellaneous), it positions itself among the top-tier journals in pharmacology and toxicology. The journal's insights are critical for scholars and practitioners aiming to enhance therapeutic efficacy and safety. Access options for the content remain traditional, thus supporting a comprehensive approach to scientific literature. Throughout its converged years up to 2024, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY continues to play a vital role in shaping pharmaceutical education and practice.

The International Journal of Pharmaceutics, a prestigious publication from ELSEVIER, stands at the forefront of the pharmaceutical science field, exemplified by its impressive ranking of #15 out of 183 in Pharmacology, Toxicology, and Pharmaceutics, placing it in the 92nd percentile. Established in 1978, this journal has continuously provided a platform for researchers, professionals, and students to share groundbreaking discoveries and innovations in drug formulation, delivery systems, and pharmacokinetics. With a Q1 ranking in the 2023 category of Pharmaceutical Science, it underscores its significance in disseminating high-quality research that shapes clinical practices and enhances therapeutic outcomes. While the journal does not currently offer open access options, it remains accessible to subscribers through its publication based in Amsterdam, Netherlands, ensuring a broad reach within the scientific community. As it converges towards a vibrant future, the International Journal of Pharmaceutics continues to be an essential resource for anyone dedicated to advancing the field of pharmacy and drug development.